Tine Jess
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tine Jess has a total of 445 co-authors. Here are the top co-authors by number of shared publications:
- Kristine Højgaard Allin
Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
22 shared publications - Manasi Agrawal
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
10 shared publications - Rahma Elmahdi
PREDICT Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
9 shared publications - Gry Poulsen
Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
6 shared publications - Lone Larsen
Department of Gastroenterology and Hepatology, Aalborg University Hospital , Aalborg
6 shared publications - Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
5 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Gut microbiota composition outperforms chronological age in predicting systemic inflammation and incident disease risk
Low-grade systemic inflammation increases with age and accompanies many age-associated lifestyle-related diseases, yet substantial inter-individual variability exists beyond chronological age. Given the gut microbiotaâs role in immune regulation, we analyzed paired fecal microbiota profiles, 30 plasma cytokines, and 19 biochemical and physiological measures in 1,199 adults (aged 20-72) from the population-based DanFunD cohort to assess the relative associations of microbiota composition and age with systemic inflammation and subsequent disease risk. Here we show that despite an association between age and 40% of inflammatory cytokines and most physiological variables, gut microbiota composition explained more variance than age for 97% of cytokines and 84% of physiological variables. Individuals with the Bacteroides 2 enterotype exhibited elevated pro-inflammatory cytokines and adverse metabolic profiles already in early adulthood, displaying an inflammaging-like phenotype up to 37 years earlier than other enterotypes. This enterotype was associated with increased risk of future incident disease across multiple organ systems (hazard ratio 1.21), with mediation analyses suggesting that inflammatory cytokines accounted for part of this association. Conversely, a high-diversity enterotype was linked to lower inflammation and reduced disease risk. These findings position gut microbiota composition as a stronger correlate of systemic inflammatory tone than chronological age and a potentially modifiable determinant of inflammation-related disease trajectories across adulthood.
- 8 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessGut microbiota composition outperforms chronological age in predicting systemic inflammation and incident disease risk
Low-grade systemic inflammation increases with age and accompanies many age-associated lifestyle-related diseases, yet substantial inter-individual variability exists beyond chronological age. Given the gut microbiotaâs role in immune regulation, we analyzed paired fecal microbiota profiles, 30 plasma cytokines, and 19 biochemical and physiological measures in 1,199 adults (aged 20-72) from the population-based DanFunD cohort to assess the relative associations of microbiota composition and age with systemic inflammation and subsequent disease risk. Here we show that despite an association between age and 40% of inflammatory cytokines and most physiological variables, gut microbiota composition explained more variance than age for 97% of cytokines and 84% of physiological variables. Individuals with the Bacteroides 2 enterotype exhibited elevated pro-inflammatory cytokines and adverse metabolic profiles already in early adulthood, displaying an inflammaging-like phenotype up to 37 years earlier than other enterotypes. This enterotype was associated with increased risk of future incident disease across multiple organ systems (hazard ratio 1.21), with mediation analyses suggesting that inflammatory cytokines accounted for part of this association. Conversely, a high-diversity enterotype was linked to lower inflammation and reduced disease risk. These findings position gut microbiota composition as a stronger correlate of systemic inflammatory tone than chronological age and a potentially modifiable determinant of inflammation-related disease trajectories across adulthood.
- Open Access
- 3 July 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 23-29
Appendectomy and Subsequent Type 2 Diabetes â A National Cohort study
- 3 July 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 23-29
Open AccessAppendectomy and Subsequent Type 2 Diabetes â A National Cohort study
- Open Access
- 16 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8  (3) , otag057
Paradigm Shift in Inflammatory Bowel Disease ManagementâAdvanced Therapy Utilisation, Persistence, and Outcomes in a United Arab Emirates Cohort During 2015â2025
Background: The therapeutic landscape for inflammatory bowel disease (IBD) has expanded rapidly beyond anti-TNF agents. We characterised the evolution of advanced therapy utilisation, persistence, and outcomes in a United Arab Emirates (UAE) cohort during 2015-2025. Methods: This prospective registry study from a tertiary IBD facility in the UAE included 508 patients (333 Crohnâs disease [CD], 175 ulcerative colitis [UC]). Advanced therapies were grouped by mechanism of action. We compared prescribing patterns between 'Pre-2023' and '2023 and Beyondâ eras. Treatment persistence was analysed using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 508 patients, 380 (74.8%) received advanced therapy. In CD, first-line anti-TNF use fell from 76% (pre-2023) to 42% (2023+), with anti-IL-23 agents emerging as a major first-line option (32%). Median time to first advanced therapy decreased dramatically: CD from 23.0 to 2.0 months (p < 0.0001) and UC from 37.0 to 3.0 months (p < 0.0001). Anti-IL-23 agents demonstrated significantly superior persistence in CD first-line therapy (p = 0.011 vs anti-TNF). In multivariable analysis, anti-IL-23 therapy was associated with significantly lower discontinuation risk (HR: 0.35, 95% CI: 0.19-0.64, p = 0.0008). Infliximab persistence appeared to improve over time, with significantly better 1-year persistence in 2024+ versus 2018-2019 (pairwise p = 0.020; overall trend p = 0.05). A shift in UC second-line prescribing was also observed (p = 0.048). Early surgery rates were low across both eras (CD: 6.5% vs 3.9%; UC: 2.5% vs 1.9%) with no significant difference in 35-month surgery-free survival, though this analysis was underpowered. Conclusions: IBD management in the UAE has undergone a rapid paradigm shift since 2023, characterised by earlier therapy initiation and diversification away from anti-TNF dominance, particularly in CD. Superior persistence of anti-IL-23 agents in our cohort is consistent with this evolution in clinical practice and supports its further evaluation.
- 16 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8  (3) , otag057
Open AccessParadigm Shift in Inflammatory Bowel Disease ManagementâAdvanced Therapy Utilisation, Persistence, and Outcomes in a United Arab Emirates Cohort During 2015â2025
Background: The therapeutic landscape for inflammatory bowel disease (IBD) has expanded rapidly beyond anti-TNF agents. We characterised the evolution of advanced therapy utilisation, persistence, and outcomes in a United Arab Emirates (UAE) cohort during 2015-2025. Methods: This prospective registry study from a tertiary IBD facility in the UAE included 508 patients (333 Crohnâs disease [CD], 175 ulcerative colitis [UC]). Advanced therapies were grouped by mechanism of action. We compared prescribing patterns between 'Pre-2023' and '2023 and Beyondâ eras. Treatment persistence was analysed using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 508 patients, 380 (74.8%) received advanced therapy. In CD, first-line anti-TNF use fell from 76% (pre-2023) to 42% (2023+), with anti-IL-23 agents emerging as a major first-line option (32%). Median time to first advanced therapy decreased dramatically: CD from 23.0 to 2.0 months (p < 0.0001) and UC from 37.0 to 3.0 months (p < 0.0001). Anti-IL-23 agents demonstrated significantly superior persistence in CD first-line therapy (p = 0.011 vs anti-TNF). In multivariable analysis, anti-IL-23 therapy was associated with significantly lower discontinuation risk (HR: 0.35, 95% CI: 0.19-0.64, p = 0.0008). Infliximab persistence appeared to improve over time, with significantly better 1-year persistence in 2024+ versus 2018-2019 (pairwise p = 0.020; overall trend p = 0.05). A shift in UC second-line prescribing was also observed (p = 0.048). Early surgery rates were low across both eras (CD: 6.5% vs 3.9%; UC: 2.5% vs 1.9%) with no significant difference in 35-month surgery-free survival, though this analysis was underpowered. Conclusions: IBD management in the UAE has undergone a rapid paradigm shift since 2023, characterised by earlier therapy initiation and diversification away from anti-TNF dominance, particularly in CD. Superior persistence of anti-IL-23 agents in our cohort is consistent with this evolution in clinical practice and supports its further evaluation.
- 10 June 2026
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 11  (7) , 546-549
Breaking the cycle: from documenting data scarcity to enabling global IBD research
- 10 June 2026
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 11  (7) , 546-549
Breaking the cycle: from documenting data scarcity to enabling global IBD research
- Open Access
- 1 June 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunityâfindings from the UAE Epi-IBD study
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunityâfindings from the UAE Epi-IBD study
- 1 June 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Open AccessRapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunityâfindings from the UAE Epi-IBD study
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunityâfindings from the UAE Epi-IBD study
- 10 March 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20  (3)
Real-world evidence on medication patterns in inflammatory bowel disease the first decade after diagnosis
Background and Aims: Medical treatment of inflammatory bowel disease (IBD) is complex and highly dynamic. This study conducts an extensive population-wide analysis of real-world treatment patterns in ulcerative colitis (UC) and Crohnâs disease (CD) to provide population-based estimates to patients, clinicians, and healthcare systems. Methods: Using Danish nationwide registers, we followed individuals diagnosed with IBD during 2003-2023 in Denmark for up to 10 years. Focusing on 5-aminosalicylic acid (5-ASA), corticosteroids, methotrexate, thiopurines, and advanced therapies (biological and small molecule drugs), we examined cumulative use, use per year after diagnosis, and treatment combinations. Analyses were stratified on sex, age, and calendar year at diagnosis. Results: In 36 179 individuals with IBD (25 870 UC; 10 309 CD), the 10-year cumulative use of immunomodulators and/or advanced therapies was 37.0% in UC and 74.9% in CD. Long-term treatment was dominated by advanced therapies in CD and 5-ASA in UC. The cumulative use of corticosteroids in UC and 5-ASA in CD declined in recent years, whereas the use of advanced therapies rose in both UC and CD. The use of advanced therapies decreased with increasing age at diagnosis. In the tenth year after diagnosis, approximately half of patients (UC: 43.8% and CD: 50.8%) did not receive any medication. Conclusions: In this population-based real-world medication study, we observed that 5-ASA remains the mainstay of treatment for UC, whereas advanced therapies dominate long-term treatment for CD. Of note, half of patients did not receive any medical treatment in the tenth year after diagnosis.
- 10 March 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20  (3)
Real-world evidence on medication patterns in inflammatory bowel disease the first decade after diagnosis
Background and Aims: Medical treatment of inflammatory bowel disease (IBD) is complex and highly dynamic. This study conducts an extensive population-wide analysis of real-world treatment patterns in ulcerative colitis (UC) and Crohnâs disease (CD) to provide population-based estimates to patients, clinicians, and healthcare systems. Methods: Using Danish nationwide registers, we followed individuals diagnosed with IBD during 2003-2023 in Denmark for up to 10 years. Focusing on 5-aminosalicylic acid (5-ASA), corticosteroids, methotrexate, thiopurines, and advanced therapies (biological and small molecule drugs), we examined cumulative use, use per year after diagnosis, and treatment combinations. Analyses were stratified on sex, age, and calendar year at diagnosis. Results: In 36 179 individuals with IBD (25 870 UC; 10 309 CD), the 10-year cumulative use of immunomodulators and/or advanced therapies was 37.0% in UC and 74.9% in CD. Long-term treatment was dominated by advanced therapies in CD and 5-ASA in UC. The cumulative use of corticosteroids in UC and 5-ASA in CD declined in recent years, whereas the use of advanced therapies rose in both UC and CD. The use of advanced therapies decreased with increasing age at diagnosis. In the tenth year after diagnosis, approximately half of patients (UC: 43.8% and CD: 50.8%) did not receive any medication. Conclusions: In this population-based real-world medication study, we observed that 5-ASA remains the mainstay of treatment for UC, whereas advanced therapies dominate long-term treatment for CD. Of note, half of patients did not receive any medical treatment in the tenth year after diagnosis.
- 3 March 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121  (11) , 2677-2686
Phenotypic Presentation of Pediatric Inflammatory Bowel Disease Through 4 Decades: The Pediatric NorDIBD Cohort
INTRODUCTION: The incidence of pediatric inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is increasing worldwide. Thus, a thorough understanding of the development and presentation of pediatric IBD is essential. This study aims to establish and characterize a comprehensive population-based cohort of all patients with pediatric IBD in the North Denmark Region spanning 4 decades. METHODS: We identified all children (n = 468) diagnosed with IBD in the North Denmark Region (589,936 inhabitants) during 1978â2020, establishing the Pediatric NorDIBD cohort. Patient characteristics were manually gathered from medical records. We examined developments in incidence, disease presentation, and family history of IBD over time. RESULTS: A total of 244 children with UC and 224 children with CD were diagnosed during 1978â2020. Incidence rate of pediatric IBD had increased 272%. The proportion of CD had increased. The median age at diagnosis was 15.4 years for both UC and CD and increased over time. In UC, the proportions of children diagnosed with pancolitis increased over time. For CD, most children were diagnosed with ileocolonic (39.3%) or colonic (40.2%) disease, and the proportion presenting with ileocolonic and penetrating CD increased over time. The 13% of patients who had a first-degree relative with IBD were younger at diagnosis. DISCUSSION: The newly established unselected population-based pediatric NorDIBD cohort shows an increase in both incidence and extensiveness of newly diagnosed pediatric IBD over the last 4 decades and provides a foundation for future research into the long-term outcomes of pediatric IBD.
- 3 March 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121  (11) , 2677-2686
Phenotypic Presentation of Pediatric Inflammatory Bowel Disease Through 4 Decades: The Pediatric NorDIBD Cohort
INTRODUCTION: The incidence of pediatric inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is increasing worldwide. Thus, a thorough understanding of the development and presentation of pediatric IBD is essential. This study aims to establish and characterize a comprehensive population-based cohort of all patients with pediatric IBD in the North Denmark Region spanning 4 decades. METHODS: We identified all children (n = 468) diagnosed with IBD in the North Denmark Region (589,936 inhabitants) during 1978â2020, establishing the Pediatric NorDIBD cohort. Patient characteristics were manually gathered from medical records. We examined developments in incidence, disease presentation, and family history of IBD over time. RESULTS: A total of 244 children with UC and 224 children with CD were diagnosed during 1978â2020. Incidence rate of pediatric IBD had increased 272%. The proportion of CD had increased. The median age at diagnosis was 15.4 years for both UC and CD and increased over time. In UC, the proportions of children diagnosed with pancolitis increased over time. For CD, most children were diagnosed with ileocolonic (39.3%) or colonic (40.2%) disease, and the proportion presenting with ileocolonic and penetrating CD increased over time. The 13% of patients who had a first-degree relative with IBD were younger at diagnosis. DISCUSSION: The newly established unselected population-based pediatric NorDIBD cohort shows an increase in both incidence and extensiveness of newly diagnosed pediatric IBD over the last 4 decades and provides a foundation for future research into the long-term outcomes of pediatric IBD.
- Open Access
Gestational Environment Captured by the Neonatal Metabolome is not Predictive of Later Inflammatory Bowel Disease
Background: Gestational exposures may contribute to the newbornâs lifetime risk of inflammatory bowel disease (IBD). While gestational influences are associated with IBD onset, the causality and confounding of such exposures are difficult to ascertain. The neonatal metabolome provides a metabolic snapshot of gestational influences. Objective: We tested the neonatal metabolomeâs ability to predict future IBD, to assess whether gestational exposures are reflected in early molecular precursors of the disease. Methods: We profiled dried blood spots from 520 newborns who later developed IBD and matched controls using high-resolution untargeted mass spectrometry metabolomics (1,350 QC-passing metabolites). Genotyping was available for 1,009 of these individuals. PERMANOVA confirmed assay sensitivity to gestational exposures, gradient boosting was used for prediction. Results: The neonatal metabolome significantly captured maternal smoking, birth weight, and gestational age (p < 0.001), but explained minimal variance in IBD status (R 2 = 0.09%, p = 0.390) and showed no predictive power for IBD (AUC = 0.51, 95% CI 0.50â0.52, p = 0.585). Stratifying by disease subtype and age of onset did not improve performance. In contrast, genetic risk scores were modestly predictive (CD: AUC = 0.64, p < 5.11Ă10âť 14 ; UC: AUC = 0.63, p < 7.65Ă10âťÂšÂ˛), but uncorrelated with neonatal metabolomic profiles (CD: p = 0.650; UC: p = 0.970), suggesting a later-age effect. Conclusions: Using a large, comprehensively profiled cohort, we demonstrate that neonatal metabolomic profiles sensitively capture gestational signatures, but not the overall future IBD risk. Our findings suggest that most IBD risk accumulates later in life, beyond gestational molecular imprints.
Open AccessGestational Environment Captured by the Neonatal Metabolome is not Predictive of Later Inflammatory Bowel Disease
Background: Gestational exposures may contribute to the newbornâs lifetime risk of inflammatory bowel disease (IBD). While gestational influences are associated with IBD onset, the causality and confounding of such exposures are difficult to ascertain. The neonatal metabolome provides a metabolic snapshot of gestational influences. Objective: We tested the neonatal metabolomeâs ability to predict future IBD, to assess whether gestational exposures are reflected in early molecular precursors of the disease. Methods: We profiled dried blood spots from 520 newborns who later developed IBD and matched controls using high-resolution untargeted mass spectrometry metabolomics (1,350 QC-passing metabolites). Genotyping was available for 1,009 of these individuals. PERMANOVA confirmed assay sensitivity to gestational exposures, gradient boosting was used for prediction. Results: The neonatal metabolome significantly captured maternal smoking, birth weight, and gestational age (p < 0.001), but explained minimal variance in IBD status (R 2 = 0.09%, p = 0.390) and showed no predictive power for IBD (AUC = 0.51, 95% CI 0.50â0.52, p = 0.585). Stratifying by disease subtype and age of onset did not improve performance. In contrast, genetic risk scores were modestly predictive (CD: AUC = 0.64, p < 5.11Ă10âť 14 ; UC: AUC = 0.63, p < 7.65Ă10âťÂšÂ˛), but uncorrelated with neonatal metabolomic profiles (CD: p = 0.650; UC: p = 0.970), suggesting a later-age effect. Conclusions: Using a large, comprehensively profiled cohort, we demonstrate that neonatal metabolomic profiles sensitively capture gestational signatures, but not the overall future IBD risk. Our findings suggest that most IBD risk accumulates later in life, beyond gestational molecular imprints.
- Open Access
- 21 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Multimodal analysis disentangles the genetic and microbial associations between inflammatory bowel disease and other immune-mediated diseases across a harmonized population framework
Immune-mediated inflammatory diseases (IMID) are chronic conditions with a well-established multifaceted association with the gastrointestinal diseases Crohnâs disease (CD) and ulcerative colitis (UC), commonly known as inflammatory bowel disease (IBD). In this study, we leverage Danish nationwide pedigree and health data, genome-wide association studies, and fecal microbiota data to characterize the association between IBD and other IMIDs and disentangle genetic and environmental contributions. We show that CD and UC have distinct patterns of correlations with other IMIDs within families. By evaluating genetic and gut microbial correlations, we highlight a UC microbiota-linked correlation with multiple sclerosis and systemic lupus erythematosus despite a negative genetic correlation, suggesting a key role for environmental factors. In contrast, we find consistent genetic and microbial convergence between both IBD subtypes and rheumatoid arthritis, whereas genetic factors mainly drive the correlation with psoriasis. Thus, our findings uncover heterogeneity in shared etiological pathways across immune diseases, underscoring the need for stratified approaches to diagnosing and treating IBD.
- 21 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessMultimodal analysis disentangles the genetic and microbial associations between inflammatory bowel disease and other immune-mediated diseases across a harmonized population framework
Immune-mediated inflammatory diseases (IMID) are chronic conditions with a well-established multifaceted association with the gastrointestinal diseases Crohnâs disease (CD) and ulcerative colitis (UC), commonly known as inflammatory bowel disease (IBD). In this study, we leverage Danish nationwide pedigree and health data, genome-wide association studies, and fecal microbiota data to characterize the association between IBD and other IMIDs and disentangle genetic and environmental contributions. We show that CD and UC have distinct patterns of correlations with other IMIDs within families. By evaluating genetic and gut microbial correlations, we highlight a UC microbiota-linked correlation with multiple sclerosis and systemic lupus erythematosus despite a negative genetic correlation, suggesting a key role for environmental factors. In contrast, we find consistent genetic and microbial convergence between both IBD subtypes and rheumatoid arthritis, whereas genetic factors mainly drive the correlation with psoriasis. Thus, our findings uncover heterogeneity in shared etiological pathways across immune diseases, underscoring the need for stratified approaches to diagnosing and treating IBD.
- Open Access
- 29 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6  (1)
Maternal mid-pregnancy dietary patterns and inflammatory bowel disease in offspring from a prospective cohort study
Background: Maternal diet during pregnancy may shape the childâs immune system and gut microbiota maturation, potentially influencing the risk of developing inflammatory bowel disease (IBD). Therefore, we examined maternal a posteriori dietary patterns during pregnancy and their associations with pediatric-onset IBD risk in offspring. Methods: The study comprised mother-child pairs from the Danish National Birth Cohort, which is a nationwide cohort of Danish pregnant mothers and their children, enrolled in 1996-2002 and followed prospectively through national health registers. Maternal dietary patterns during pregnancy were identified using k-means cluster analysis of 37 food group intakes, assessed with a food frequency questionnaire in gestational week 25 (second trimester). Pediatric-onset IBD cases (diagnosed at â¤18 years) were identified in Danish health registers. Cox regression explored associations between maternal dietary patterns during pregnancy and risk of pediatric-onset IBD in offspring, using the most common dietary pattern as reference. Results: Based on analysis of 56,097 mother-child pairs, of which 161 (0.29%) offspring developed pediatric-onset IBD, we identify five distinct maternal dietary patterns: diverse (n = 8388), non-recommended (n = 14,110), Mediterranean (n = 14,700), animal-based (n = 3808), and Western (n = 15,091). Notably, a diverse dietary pattern, characterized by high intakes of most food groups, is associated with 45% lower risk of pediatric-onset IBD in offspring compared to a Western pattern (hazard ratio: 0.55; 95% confidence interval: 0.31â0.97). No significant associations are observed for the other patterns. Conclusions: This large prospective cohort study shows that maternal adherence to a diverse dietary pattern during pregnancy may contribute to lower risk of pediatric-onset IBD in offspring.
- 29 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6  (1)
Open AccessMaternal mid-pregnancy dietary patterns and inflammatory bowel disease in offspring from a prospective cohort study
Background: Maternal diet during pregnancy may shape the childâs immune system and gut microbiota maturation, potentially influencing the risk of developing inflammatory bowel disease (IBD). Therefore, we examined maternal a posteriori dietary patterns during pregnancy and their associations with pediatric-onset IBD risk in offspring. Methods: The study comprised mother-child pairs from the Danish National Birth Cohort, which is a nationwide cohort of Danish pregnant mothers and their children, enrolled in 1996-2002 and followed prospectively through national health registers. Maternal dietary patterns during pregnancy were identified using k-means cluster analysis of 37 food group intakes, assessed with a food frequency questionnaire in gestational week 25 (second trimester). Pediatric-onset IBD cases (diagnosed at â¤18 years) were identified in Danish health registers. Cox regression explored associations between maternal dietary patterns during pregnancy and risk of pediatric-onset IBD in offspring, using the most common dietary pattern as reference. Results: Based on analysis of 56,097 mother-child pairs, of which 161 (0.29%) offspring developed pediatric-onset IBD, we identify five distinct maternal dietary patterns: diverse (n = 8388), non-recommended (n = 14,110), Mediterranean (n = 14,700), animal-based (n = 3808), and Western (n = 15,091). Notably, a diverse dietary pattern, characterized by high intakes of most food groups, is associated with 45% lower risk of pediatric-onset IBD in offspring compared to a Western pattern (hazard ratio: 0.55; 95% confidence interval: 0.31â0.97). No significant associations are observed for the other patterns. Conclusions: This large prospective cohort study shows that maternal adherence to a diverse dietary pattern during pregnancy may contribute to lower risk of pediatric-onset IBD in offspring.